Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.

about

Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.

Item

http://www.wikidata.org/entity/Q48243797

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@en

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@nl

type

Item

label

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@en

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@nl

prefLabel

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@en

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@nl

P1476

Phase II study of doxorubicin ...... ctory aggressive fibromatosis.

@en

P2093

Huijie Wang

http://www.w3.org/2001/XMLSchema#string

Xianghua Wu

http://www.w3.org/2001/XMLSchema#string

Xiaonan Hong

http://www.w3.org/2001/XMLSchema#string

Xin Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Activity of Sorafenib against desmoid tumor/deep fibromatosis

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).

High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

Desmoid tumors: clinical features and treatment options for advanced disease

Combination chemotherapy in adult desmoid tumors.

Extra-abdominal desmoid tumors associated with familial adenomatous polyposis

Proof of principle for bevacizumab activity in desmoid-type fibromatosis

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

P2888

s10637-017-0542-0

P304

114-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-017-0542-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zhiguo Luo

P577

2017-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29170886

http://www.w3.org/2001/XMLSchema#string

P921

thalidomide